Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IDIX's Cash to Debt is ranked higher than
95% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. IDIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
IDIX' s 10-Year Cash to Debt Range
Min: 2.47  Med: 84.55 Max: No Debt
Current: No Debt
Equity to Asset 0.77
IDIX's Equity to Asset is ranked higher than
62% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IDIX: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
IDIX' s 10-Year Equity to Asset Range
Min: -0.74  Med: 0.52 Max: 0.88
Current: 0.77
-0.74
0.88
Interest Coverage No Debt
IDIX's Interest Coverage is ranked higher than
92% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IDIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IDIX' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 41.37
M-Score: 67.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 550.02
IDIX's Operating margin (%) is ranked higher than
100% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. IDIX: 550.02 )
Ranked among companies with meaningful Operating margin (%) only.
IDIX' s 10-Year Operating margin (%) Range
Min: -26379.53  Med: -522.56 Max: -8.59
Current: 550.02
-26379.53
-8.59
Net-margin (%) 545.06
IDIX's Net-margin (%) is ranked higher than
99% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. IDIX: 545.06 )
Ranked among companies with meaningful Net-margin (%) only.
IDIX' s 10-Year Net-margin (%) Range
Min: -26073.99  Med: -512.01 Max: -6.55
Current: 545.06
-26073.99
-6.55
ROE (%) -109.36
IDIX's ROE (%) is ranked lower than
82% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. IDIX: -109.36 )
Ranked among companies with meaningful ROE (%) only.
IDIX' s 10-Year ROE (%) Range
Min: -5602  Med: -75.22 Max: -15.36
Current: -109.36
-5602
-15.36
ROA (%) -86.85
IDIX's ROA (%) is ranked lower than
81% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. IDIX: -86.85 )
Ranked among companies with meaningful ROA (%) only.
IDIX' s 10-Year ROA (%) Range
Min: -627.45  Med: -58.43 Max: -4.91
Current: -86.85
-627.45
-4.91
ROC (Joel Greenblatt) (%) -5826.62
IDIX's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. IDIX: -5826.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IDIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5324.09  Med: -674.19 Max: -150.73
Current: -5826.62
-5324.09
-150.73
Revenue Growth (3Y)(%) -100.00
IDIX's Revenue Growth (3Y)(%) is ranked lower than
92% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. IDIX: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IDIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -19.40 Max: 235.2
Current: -100
-100
235.2
EBITDA Growth (3Y)(%) 3.50
IDIX's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. IDIX: 3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IDIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.4  Med: -18.40 Max: 105.7
Current: 3.5
-69.4
105.7
EPS Growth (3Y)(%) 1.50
IDIX's EPS Growth (3Y)(%) is ranked higher than
59% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. IDIX: 1.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IDIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -77.4  Med: -16.70 Max: 114
Current: 1.5
-77.4
114
» IDIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IDIX Guru Trades in Q4 2013

Steven Cohen 13,900 sh (New)
Jeremy Grantham 56,100 sh (+159.72%)
Seth Klarman 36,910,868 sh (+24.42%)
Seth Klarman 36,910,868 sh (+37.90%)
Chuck Royce 665,980 sh (-9.51%)
» More
Q1 2014

IDIX Guru Trades in Q1 2014

Steven Cohen 96,000 sh (+590.65%)
Seth Klarman 53,331,109 sh (+44.49%)
Seth Klarman 53,331,109 sh (unchged)
Jeremy Grantham Sold Out
Chuck Royce 534,316 sh (-19.77%)
» More
Q2 2014

IDIX Guru Trades in Q2 2014

Prem Watsa 50,400 sh (New)
Mario Gabelli 142,184 sh (New)
Seth Klarman 53,331,109 sh (unchged)
Chuck Royce Sold Out
» More
Q3 2014

IDIX Guru Trades in Q3 2014

Mario Gabelli Sold Out
Prem Watsa Sold Out
Seth Klarman Sold Out
Seth Klarman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 24.26
IDIX's P/B is ranked lower than
94% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. IDIX: 24.26 )
Ranked among companies with meaningful P/B only.
IDIX' s 10-Year P/B Range
Min: 1.28  Med: 6.67 Max: 74.22
Current: 24.26
1.28
74.22
Current Ratio 6.59
IDIX's Current Ratio is ranked higher than
62% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. IDIX: 6.59 )
Ranked among companies with meaningful Current Ratio only.
IDIX' s 10-Year Current Ratio Range
Min: 1.75  Med: 3.93 Max: 17.46
Current: 6.59
1.75
17.46
Quick Ratio 6.59
IDIX's Quick Ratio is ranked higher than
63% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. IDIX: 6.59 )
Ranked among companies with meaningful Quick Ratio only.
IDIX' s 10-Year Quick Ratio Range
Min: 1.75  Med: 3.93 Max: 17.46
Current: 6.59
1.75
17.46
Days Sales Outstanding 1096.56
IDIX's Days Sales Outstanding is ranked lower than
100% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. IDIX: 1096.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDIX' s 10-Year Days Sales Outstanding Range
Min: 2  Med: 60.41 Max: 1096.56
Current: 1096.56
2
1096.56

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -4.60
IDIX's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. IDIX: -4.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDIX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.6  Med: 1.20 Max: 1.6
Current: -4.6
-4.6
1.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NO9.Germany,
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's main research and development focus is on the treatment of hepatitis C virus, or HCV. HCV is a cause of liver disease. The Company is currently developing nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication. The Company has developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1, or HIV, and acquired immune deficiency syndrome, or AIDS, for use in combination therapy. In 2008, it successfully completed a proof-of-concept clinical trial of IDX899 in treatment-naïve HIV-infected patients. In February 2009, it licensed its NNRTI compounds to GlaxoSmithKline. In collaboration with Novartis, it developed telbivudine (Tyzeka/Sebivo) through commercialization for the treatment of patients with HBV. In October 2006, the FDA approved Tyzeka in the United States and Sebivo was approved in 2007 in more than 50 countries outside the United States, including major Asian countries and several countries included in the European Union. Companies the compete with in the HCV market include Abbott Laboratories, Boehringer Ingelheim International GmbH, F. Hoffman-LaRoche & Co., Johnson & Johnson, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc., and Presidio Pharmaceuticals, Inc. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposing of hazardous materials and waste products, including certain regulations promulgated by the U.S. Environmental Protection Agency, or EPA.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK